Publications
Please refer to Cristina’s over 130 contributions at PSI’s Digital Object Repository (please be patient while loading).
The latest 20 entries shall be automatically listed here:
- Vaccarin, C., Beyer, D., Schmid, J. V., Klein, B., Jegathasan, J., Behera, S., … Müller, C. (2025). Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07602-7
- Westerbergh, F., van der Meulen, N. P., Müller, C., Grings, A., Ritt, P., & Bernhardt, P. (2025). Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls. EJNMMI Research, 15(1), 130 (13 pp.). https://doi.org/10.1186/s13550-025-01326-3
- Westerbergh, F., McDougall, L., Ritt, P., Fricke, J. G., van der Meulen, N. P., Müller, C., … Bernhardt, P. (2025). Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging. EJNMMI Physics, 12(1), 81 (14 pp.). https://doi.org/10.1186/s40658-025-00792-x
- Vaccarin, C., Beyer, D., Moiseeva, A., Favaretto, C., van der Meulen, N. P., Hunkeler, B. D., … Müller, C. (2025). Development of lisinopril radioconjugates for nuclear imaging of the angiotensin converting enzyme. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07386-w
- Beyer, D., Vaccarin, C., Schmid, J. V., Deberle, L. M., Deupi, X., Schibli, R., & Müller, C. (2025). Design and preclinical evaluation of novel uPAR-targeting radiopeptides modified with an albumin-binding entity. Molecular Pharmaceutics, 22(6), 3242-3254. https://doi.org/10.1021/acs.molpharmaceut.5c00135
- Florit, A., de Koster, E. J., Sassano, S., Alic, L., Pisano, G., van Velden, F. H. P., … Collarino, A. (2025). Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 52, 3975-3989. https://doi.org/10.1007/s00259-025-07277-0
- Ritt, P., Fernández, R., Soza-Ried, C., Nicolai, H., Amaral, H., Krieger, K., … Kramer, V. (2025). Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 52, 2431-2443. https://doi.org/10.1007/s00259-025-07102-8
- Mapanao, A. K., Busslinger, S. D., Mehta, A., Kegler, K., Favaretto, C., Grundler, P. V., … Müller, C. (2025). Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1383-1398. https://doi.org/10.1007/s00259-024-07035-8
- Chirindel, A., Nicolas, G. P., Westerbergh, F., McDougall, L., Schmid, D. E., Geistlich, S., … Schibli, R. (2025). First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1628-1630. https://doi.org/10.1007/s00259-024-07009-w
- Müller, C., & van der Meulen, N. P. (2024). Terbium "Sisters": more than just a "Swiss Army Knife". In V. Prasad (Ed.), Beyond becquerel and biology to precision radiomolecular oncology: festschrift in honor of Richard P. Baum (pp. 225-236). https://doi.org/10.1007/978-3-031-33533-4_23
- Wallimann, R. H., Mehta, A., Mapanao, A. K., Köster, U., Kneuer, R., Schindler, P., … Müller, C. (2025). Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form. European Journal of Nuclear Medicine and Molecular Imaging, 52, 1370-1382. https://doi.org/10.1007/s00259-024-07018-9
- Gomes, C. V., Mendes, B. M., Paixão, L., Gnesin, S., Müller, C., van der Meulen, N. P., … Lima, T. V. M. (2024). Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours. EJNMMI Physics, 11(1), 61 (14 pp.). https://doi.org/10.1186/s40658-024-00669-5
- Song, Y., Zou, J., Castellanos, E. A., Matsuura, N., Ronald, J. A., Shuhendler, A., … Chen, X. (2024). Theranostics – a sure cure for cancer after 100 years? Theranostics, 14(6), 2464-2488. https://doi.org/10.7150/thno.96675
- Vaccarin, C., Mapanao, A. K., Deberle, L. M., Becker, A. E., Borgna, F., Marzaro, G., … Müller, C. (2024). Design and preclinical evaluation of a novel prostate-specific membrane antigen radioligand modified with a transthyretin binder. Cancers, 16(7), 1262 (13 pp.). https://doi.org/10.3390/cancers16071262
- Wallimann, R. H., Hensinger, H., Müller, C., Schibli, R., Kneuer, R., & Schindler, P. (2024). Liquid chromatography ICP-MS to assess the stability of 175Lu- and natGa-based tumor-targeting agents towards the development of 177Lu- and 68Ga-labeled radiopharmaceuticals. Pharmaceutics, 16(3), 299 (13 pp.). https://doi.org/10.3390/pharmaceutics16030299
- Fricke, J., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., … Wild, D. (2024). First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. European Journal of Nuclear Medicine and Molecular Imaging, 51, 2517-2519. https://doi.org/10.1007/s00259-024-06641-w
- Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Busslinger, S. D., … van der Meulen, N. P. (2024). Terbium-149 production: a focus on yield and quality improvement towards preclinical application. Scientific Reports, 14(1), 3284 (12 pp.). https://doi.org/10.1038/s41598-024-53610-2
- Corpetti, M., Müller, C., Beltran, H., de Bono, J., & Theurillat, J. P. (2024). Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes. European Urology, 85(3), 193-204. https://doi.org/10.1016/j.eururo.2023.11.018
- Tschan, V. J., Busslinger, S. D., Bernhardt, P., Grundler, P. V., Zeevaart, J. R., Köster, U., … Müller, C. (2023). Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. Journal of Nuclear Medicine, 64(10), 1625-1631. https://doi.org/10.2967/jnumed.123.265524
- Busslinger, S. D., Becker, A. E., Vaccarin, C., Deberle, L. M., Renz, M. L., Groehn, V., … Müller, C. (2023). Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates. Cancers, 15(17), 4259 (19 pp.). https://doi.org/10.3390/cancers15174259